comprehensive -WSS

comprehensive

author：knowledge 2025-10-02 00:43:04 - browse：793

ASH19 CAR-T — Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Websites selling Wegovy, Zepbound ingredients targeted by FDA

focus

leisure time

WSS

Pharma needs to include young adults in clinical research

Slain Parkland victim's father speaks out following reenactment

Latigo launches with $135 million for Vertex

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Climate activists disrupt London Pride march to protest corporate sponsorship

ACIP vaccine advisory panel sees its vacancies filled

focus

comprehensive

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

Pediatricians' group reaffirms support for gender

Medicare details structure of new drug price negotiation program

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

BioMarin wins approval for gene therapy to treat hemophilia A

Bernie Sanders gets little from pharma CEOs on drug prices

United colonoscopy coverage change 'may cost lives,' doctors say

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Psychedelics group wrestles with new pharma identity

Russian court extends detention of American musician

knowledge

Calls for Trump's election interference trial to be televised part of long debate

Rivals hope for voter 'fatigue' as Trump's woes mount but base stays loyal: ANALYSIS

Russian court extends detention of American musician

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Parkland mass shooting to be reenacted for lawsuit

focus

leisure time

hotspot

entertainment